A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To compare the effect of zidovudine (AZT) given alone with the combination of AZT and acyclovir (ACV) on the human immunodeficiency virus (HIV) in persons infected with HIV, and to study the pharmacokinetics (how fast AZT reaches certain levels in blood and how long it remains), safety, and effectiveness of AZT given alone and in combination with ACV in treating HIV-infected patients. Other studies have shown that AZT offers potential benefits to specific AIDS patients when given over long time periods, and experiments in vitro (in the test tube) suggest that ACV may stimulate the action of AZT against HIV. It is necessary to obtain information on how these drugs perform in HIV-infected humans.

Key facts

Study ID
NCT00001010
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
72
Expected to finish
1990-10-01
Last updated by the study team
2021-11-04

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.